Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562149 | 0.87 | MAPT (0.58) | CHRM5CHRM3MAPTCHRM1SMN1; SMN2 | |
| SCHEMBL5466489 | 0.86 | MEN1 (0.72) | MAPTSMN1; SMN2KMT2AMEN1GLA | |
| SCHEMBL17117354 | 0.84 | POLB (0.61) | CHRM5CHRM3SMN1; SMN2POLBP2RX4 | |
| SCHEMBL5466257 | 0.84 | MTNR1A (0.58) | MAPTSMN1; SMN2POLBKMT2A | |
| SCHEMBL5462633 | 0.83 | ALDH1A1 (0.62) | CHRM5CHRM3MAPTCHRM1SMN1; SMN2 | |
| SCHEMBL5476364 | 0.83 | KDM4E (0.71) | SMN1; SMN2KMT2AMEN1NAMPT | |
| SCHEMBL29104598 | 0.82 | KMT2A (0.67) | SMN1; SMN2KMT2AMEN1NAMPT | |
| SCHEMBL16562116 | 0.81 | CHRM5 (0.56) | CHRM5CHRM3MAPTCHRM1SMN1; SMN2 | |
| SCHEMBL5462245 | 0.80 | MAPT (0.53) | CHRM5CHRM3MAPTCHRM1SMN1; SMN2 | |
| SCHEMBL17117344 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | CHRM5 161/4885CHRM3 183/4885MAPT 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.